Influenza Virus

Influenza virus belongs to the Orthomyxoviridae group, which are enveloped, segmented, single-stranded negative sense RNA viruses. The group includes three types of influenza viruses, A, B and C. Type B and C viruses only infect humans, but the type A viruses infect humans, horses, swine, other mammals, and a wide variety of domesticated and wild birds. Human influenza A and B viruses cause seasonal epidemics of disease almost every winter in the United States. The emergence of a new and very different influenza virus to infect people can cause an influenza pandemic. Influenza type C infections cause a mild respiratory illness and are not thought to cause epidemics. Each virus subtype has mutated into a variety of strains with differing pathogenic profiles; some are pathogenic to one species but not others, some are pathogenic to multiple species.

Influenza Virus Inhibitors & Antagonists

1-Deoxymannojirimycin hydrochloride

Cat. No.: HY-W009783

1-Deoxymannojirimycin hydrochloride is a selective **class I α1,2-mannosidase** inhibitor with an IC_{50} of 20 μM. 1-Deoxymannojirimycin hydrochloride is also a **N-linked glycosylation** inhibitor and inhibits **HIV1** strains. 1-Deoxymannojirimycin hydrochloride has antiviral activity.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

2'-Deoxy-2'-fluorocytidine

Cat. No.: HY-W012009

2'-Deoxy-2'-fluorocytidine, an nucleoside analog, is a potent inhibitor of **Crimean-Congo hemorrhagic fever virus (CCHFV)** replication.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

2'-Deoxy-2'-fluorouridine

Cat. No.: HY-W013403

2'-Deoxy-2'-fluorouridine can be used as an intermediate for **antiinfluenza virus** agents synthesis.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

2,3-Dehydro-2-deoxy-N-acetylneuraminic acid

(Neu5Ac2en; DANA)

Cat. No.: HY-125798

N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (Neu5Ac2en) is a potent **neuraminidase (sialidase)** inhibitor.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg

2′-Deoxy-2′-fluoroguanosine

Cat. No.: HY-W011518

2′-Deoxy-2′-fluoroguanosine, a nucleoside analog, is a potent inhibitor of **influenza virus** strains, with an EC_{90} of <0.35 μM for **influenza virus A** and **B** strains.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

3,4'-Dihydroxyflavone

(3,4'-DHF)

Cat. No.: HY-111802

3,4'-Dihydroxyflavone (3,4'-DHF) is an oral active flavonoid with antiviral activity against **Influenza A virus**.



Purity: 98.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

3,4-Dicaffeoylquinic acid

(3,4-Di-O-caffeoylquinic acid; Isochlorogenic acid B)

Cat. No.: HY-N0057

3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

3-Deoxysappanchalcone

Cat. No.: HY-N1745A

3-Deoxysappanchalcone is a naturally-occurring chalcone compound isolated from Caesalpinia sappan L. (Leguminosae), which possesses anti-allergic, antiviral, anti-inflammatory and antioxidant activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

3M-011

Cat. No.: HY-121496

3M-011 is a potent dual **toll-like receptor TLR7/8** agonist and a cytokine inducer. 3M-011 significantly inhibits **H3N2 influenza viral** replication in the nasal cavity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-Aminouridine

Cat. No.: HY-130802

5-Aminouridine can modify nucleobases and can be incorporated into the target DNA. 5-Aminouridine exhibits a wide range of biological activity and it inhibits the growth of tumors, **fungi** and **viruses**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

6-Azathymine

Cat. No.: HY-136559

6-Azathymine, a 6-nitrogen analog of thymine, is a potent **D-3-aminoisobutyrate-pyruvate aminotransferase** inhibitor. 6-Azathymine inhibits the biosynthesis of **DNA**, and has antibacterial and antiviral activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

6-Diazo-5-oxo-L-nor-Leucine

(L-6-Diazo-5-oxonorleucine; DON) Cat. No.: HY-108357

L-6-Diazo-5-oxonorleucine (L-6-Diazo-5-oxonorleucine) is a **glutaminases** antagonist with a K_i of 6 μM. L-6-Diazo-5-oxonorleucine exhibits antibacterial, antiviral and anticancer properties.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

ABMA

Cat. No.: HY-124801

ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including **viruses**, **intracellular bacteria** and **parasite**.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Acetylcysteine

(N-Acetylcysteine; N-Acetyl-L-cysteine; NAC) Cat. No.: HY-B0215

Acetylcysteine (N-Acetylcysteine) is a **mucolytic agent** which reduces the thickness of the mucus. Acetylcysteine is a **ROS** inhibitor.



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg, 5 g, 10 g

Acetylcysteine-15N

(N-Acetylcysteine-15N; N-Acetyl-L-cysteine-15N; NAC-15N) Cat. No.: HY-B0215S1

Acetylcysteine-15N (N-Acetylcysteine-15N) is the 15N-labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetylcysteine-d3

(N-Acetylcysteine-d3; N-Acetyl-L-cysteine-d3; NAC-d3) Cat. No.: HY-B0215S

Acetylcysteine-d3 (N-Acetylcysteine-d3) is the deuterium labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AEBSF hydrochloride

Cat. No.: HY-12821

AEBSF hydrochloride is an irreversible inhibitor of **serine proteases**, such as chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg

AG-1478

(Tyrphostin AG-1478; NSC 693255) Cat. No.: HY-13524

AG-1478 (Tyrphostin AG-1478) is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM. AG-1478 has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride; NSC 693255 hydrochloride)

Cat. No.: HY-13524A

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride) is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM. AG-1478 hydrochloride has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amantadine

(1-Adamantanamine; 1-Aminoadamantane) Cat. No.: HY-B0402

Amantadine (1-Adamantanamine) is an antiviral agent with activity against influenza A viruses. Amantadine blocks the proton flow through the M2 ion channel (M2 proton channel of influenza A) and thus prevents the release of viral RNA into the cytoplasm of the infected cells.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Amantadine hydrochloride (1-Adamantanamine hydrochloride; 1-Adamantylamine hydrochloride; ...)

Cat. No.: HY-B0402A

Amantadine (1-Adamantanamine) hydrochloride is an antiviral agent with activity against **influenza A** viruses. Amantadine hydrochloride blocks the proton flow through the M2 ion channel and thus prevents the release of viral RNA into the cytoplasm of the infected cells.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g, 50 g

Amantadine-d15

(1-Adamantanamine-d15; 1-Aminoadamantane-d15)

Cat. No.: HY-B0402S

Amantadine-d15 (1-Adamantanamine-d15) is the deuterium labeled Amantadine. Amantadine (1-Adamantanamine) is an antiviral agent with activity against influenza A viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amitivir

(LY 217896)

Cat. No.: HY-106817

Amitivir (LY 217896), a thiadiazole derivative, possesses broad antiviral activity against orthomyxo- and paramyxoviruses. Amitivir is effective against **influenza A** and **B** viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Andrographolide

(Andrographis)

Cat. No.: HY-N0191

Andrographolide is a **NF-κB** inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on **p50** in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.



Purity: 98.57%
Clinical Data: Launched
Size: 100 mg, 500 mg

Aprotinin

Cat. No.: HY-P0017

Aprotinin is a **bovine pancreatic trypsin inhibitor (BPTI)** inhibitor which inhibits **trypsin** and **chymotrypsin** with K_is of 0.06 pM and 9 nM, respectively.

Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Arctigenin

((-)-Arctigenin)

Cat. No.: HY-N0035

Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (**influenza A virus**) activities.



Purity: 99.69%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Aurintricarboxylic acid

Cat. No.: HY-122575

Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive **P2X1Rs** and **P2X3Rs**, with IC_{50}s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Azadirachtin B

Cat. No.: HY-133108

Azadirachtin B is an limonoid isolated from seed kernels of Azadirachta indica. Azadirachtin B increases alkaline phosphatase (ALP) activity and stimulates osteoblast differentiation. Azadirachtin B is active against the **Epstein-Barr virus early antigen (EBV-EA)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Baicalein

(5,6,7-Trihydroxyflavone)

Cat. No.: HY-N0196

Baicalein (5,6,7-Trihydroxyflavone) is a **xanthine oxidase** inhibitor with an IC_{50} value of 3.12 μM.



Purity: 99.13%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Baloxavir

(Baloxavir acid; S-033447)

Cat. No.: HY-109025A

Baloxavir (Baloxavir acid), derived from the prodrug Baloxavir marboxil, is a first-in-class, potent and selective **cap-dependent endonuclease (CEN)** inhibitor within the polymerase PA subunit of **influenza A** and **B viruses**.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Baloxavir marboxil

(S-033188) Cat. No.: HY-109025

Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent **endonuclease**. Baloxavir marboxil, a potent antiviral agent, shows activity against **influenza A** and **B** virus.



Purity: 98.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Baloxavir-d5

(Baloxavir acid-d5; S-033447-d5) Cat. No.: HY-109025AS

Baloxavir-d5 is deuterium labeled Baloxavir. Baloxavir (Baloxavir acid), derived from the prodrug Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Camphor

((±)-Camphor) Cat. No.: HY-N0808

Camphor ((±)-Camphor) is a topical anti-infective and anti-pruritic and internally as a stimulant and carminative. However, Camphor is poisonous when ingested. Antiviral, antitussive, and anticancer activities. Camphor is a **TRPV3** agonist.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Camphor-d6

((±)-Camphor-d6) Cat. No.: HY-N0808S

Camphor-d6 ((±)-Camphor-d6) is the deuterium labeled Camphor. Camphor ((±)-Camphor) is a topical anti-infective and anti-pruritic and internally as a stimulant and carminative. However, Camphor is poisonous when ingested.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Camptothecin

(Campathecin; (S)-(+)-Camptothecin; CPT) Cat. No.: HY-16560

Camptothecin (CPT), a kind of alkaloid, is a **DNA topoisomerase I (Topo I) inhibitor** with an IC_{50} of 679 nM.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Camptothecin-d5

(Campathecin-d5; (S)-(+)-Camptothecin-d5; CPT-d5) Cat. No.: HY-16560S

Camptothecin-d5 (Campathecin-d5) is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a **DNA topoisomerase I (Topo I) inhibitor** with an IC_{50} of 679 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-10

Cat. No.: HY-143757

Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (**CEN**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-11

Cat. No.: HY-143760

Cap-dependent endonuclease-IN-11 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-11 has the potential for the research of viral infections (extracted from patent WO2021129602A1, compound DSC126).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-12

Cat. No.: HY-143762

Cap-dependent endonuclease-IN-12 (EXP-35) is a potent Cap-dependent endonuclease inhibitor with low cytotoxicity. Cap-dependent endonuclease-IN-12 shows inhibitory activity against H1N1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-13

Cat. No.: HY-143766

Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-14

Cat. No.: HY-143768

Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-15

Cat. No.: HY-143769

Cap-dependent endonuclease-IN-15 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-15 inhibits the replication of influenza virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-16

Cat. No.: HY-143770

Cap-dependent endonuclease-IN-16 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-16 is a pyridone polycyclic derivative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-17

Cat. No.: HY-143771

Cap-dependent endonuclease-IN-17 is a **cap-dependent endonuclease (CEN)** inhibitor. Cap-dependent endonuclease-IN-17 shows antiviral activity against **influenza virus A/Hanfang/359/95 (H3N2)** with IC_{50} of 1.29 μM (CN112898346A; DSC701).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-18

Cat. No.: HY-143774S

Cap-dependent endonuclease-IN-18 is a potent **cap-dependent endonuclease (CEN)** inhibitor (CN112898312A, compound 14).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-19

Cat. No.: HY-144065

Cap-dependent endonuclease-IN-19 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-19 is a spirocyclic pyridone derivative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-2

Cat. No.: HY-143743

Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (**CEN**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-20

Cat. No.: HY-143775

Cap-dependent endonuclease-IN-20 is a **cap-dependent endonuclease (CEN)** inhibitor. Cap-dependent endonuclease-IN-20 shows antiviral activity against **influenza virus A/Hanfang/359/95 (H3N2)** with IC_{50} of 4.82 μM (CN112940009A; DSC801).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-21

Cat. No.: HY-144066

Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-22

Cat. No.: HY-143776

Cap-dependent endonuclease-IN-22 is a potent cap-dependent endonuclease **(CEN)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-23

Cat. No.: HY-144067

Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-24

Cat. No.: HY-143779

Cap-dependent endonuclease-IN-24 is a potent **cap-dependent endonuclease (CEN)** inhibitor (CN112876510A, DSC1103).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-25

Cat. No.: HY-144068

Cap-dependent endonuclease-IN-25 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-25 is a macrocyclic pyridotriazine derivative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-26

Cat. No.: HY-143781

Cap-dependent endonuclease-IN-26 is a **cap-dependent endonuclease (CEN)** inhibitor with an IC_{50} of 286 nM. Cap-dependent endonuclease-IN-26 shows antiviral activity against many **influenza A** and **B strains**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-3

Cat. No.: HY-143744

Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (**CEN**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-4

Cat. No.: HY-109025BS

Cap-dependent endonuclease-IN-4 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-4 is a polycyclic carbamoylpyridone derivative.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-5

Cat. No.: HY-143747

Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent endonuclease (**CEN**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-6

Cat. No.: HY-143749

Cap-dependent endonuclease-IN-6 (compound 13) is a cap-dependent endonuclease **(CEN)** inhibitor. Cap-dependent endonuclease-IN-6 shows inhibition against influenza virus (EC_{50}=38.21 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-7

Cat. No.: HY-143750

Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (**CEN**). Cap-dependent endonuclease-IN-7 Inhibits the synthesis of viral mRNA and eventually inhibits virus proliferation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-8

Cat. No.: HY-143752

Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (**CEN**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cap-dependent endonuclease-IN-9

Cat. No.: HY-143755

Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (**CEN**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Carbodine

Cat. No.: HY-128718

Carbodine (Carbocyclic cytidine) is a broad-spectrum antiviral agent active against DNA viruses, (+)RNA viruses, (-)RNA viruses, paramyxo, rhabdo and (+/-)RNA viruses, targets CTP synthetase that converts UTP to CTP.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Catechin

((+)-Catechin; Cianidanol; Catechuic acid)

Cat. No.: HY-N0898

Catechin ((+)-Catechin) inhibits cyclooxygenase-1 (**COX-1**) with an IC_{50} of 1.4 μM.



Purity: 98.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

CBS1117

Cat. No.: HY-131059

CBS1117 is a virus entry inhibitor with an IC_{50} of 70 nM for **influenza A virus, A/Puerto Rico/8/34** (**H1N1**). CBS1117 interferes with the hemagglutinin (HA)-mediated fusion process.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CEF1, Influenza Matrix Protein M1 (58-66)

Cat. No.: HY-P0137

CEF1, Influenza Matrix Protein M1 (58-66) is an epitope derived from the matrix protein of the influenza A virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CEF3

Cat. No.: HY-P0289

CEF3 (SIIPSGPLK) corresponds to aa 13-21 of the influenza A virus M1 protein. The matrix (M1) protein of influenza A virus is a multifunctional protein that plays essential structural and functional roles in the virus life cycle.

SIIPSGPLK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CEF6

Cat. No.: HY-P0313

CEF6 is a 9-aa-long peptide corresponding to aa 418-426 of the influenza A virus (H1N1) nucleocapsid protein.

LPFDKTTVM

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cephaeline

((-)-Cephaeline; NSC 32944 free base)

Cat. No.: HY-N4118

Cephaeline is a phenolic alkaloid in Indian Ipecac roots. Cephaeline exhibits potent inhibition of both Zika virus (ZIKV) and Ebola virus (EBOV) infections.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cephaeline hydrochloride

((-)-Cephaeline hydrochloride; NSC 32944 monohydrochloride)

Cat. No.: HY-N2076

Cephaeline hydrochloride ((-)-Cephaeline hydrochloride) is a phenolic alkaloid in Indian Ipecac roots. Cephaeline hydrochloride exhibits potent inhibition of both Zika virus (ZIKV) and Ebola virus (EBOV) infections.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Cephalotaxine

((-)-Cephalotaxine; ZINC19795976)

Cat. No.: HY-N0838

Cephalotaxlen ((-)-Cephalotaxine) is an alkaloid that can be isolated from Cephalotaxus drupacea, with antileukemic and antiviral activities. Cephalotaxlen has anti-ZIKV (Zika virus) activity.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chebulagic acid

Cat. No.: HY-N1996

Chebulagic acid is a **COX-LOX** dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a **M2 serine to asparagine 31 mutation (S31N)** inhibitor and influenza antiviral.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Chelidonine

Cat. No.: HY-N2369

Chelidonine is an isoquinoline alkaloid isolated from Chelidonium majus L., causes $G_{2/M}$ arrest and induces caspase-dependent and caspase-independent **apoptosis**, with anticancer and antiviral activity.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Chlorogenic acid

(3-O-Caffeoylquinic acid; Heriguard; NSC-407296)

Cat. No.: HY-N0055

Chlorogenic acid is a major phenolic compound in coffee and tea.



Purity: 99.55%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 500 mg

Chloroxylenol

(4-Chloro-3,5-dimethylphenol; PCMX)

Cat. No.: HY-B1414

Chloroxylenol is a broad spectrum antimicrobial chemical compound used to control bacteria, algae, fungi and virus. Target: Antibacterial
Chloroxylenol is used in hospitals and households for disinfection and sanitation.



Purity: 99.24%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g

Chloroxylenol-d6

(4-Chloro-3,5-dimethylphenol-d6; PCMX-d6)

Cat. No.: HY-B1414S

Chloroxylenol-d6 (4-Chloro-3,5-dimethylphenol-d6) is the deuterium labeled Chloroxylenol. Chloroxylenol is a broad spectrum antimicrobial chemical compound used to control bacteria, algae, fungi and virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Cinanserin hydrochloride

(SQ 10643)

Cat. No.: HY-100943

Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity **5-HT$_2$ receptor** antagonist with a K_i of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the **5-HT$_2$** than for the 5-HT$_1$ receptor (K_i of 3500 nM).



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Clemastanin B

Cat. No.: HY-N6025

Clemastanin B, a lignin, has potent **anti-influenza** activities by inhibiting the virus multiplication, prophylaxis and blocking the virus attachment. Clemastanin B targets viral endocytosis, uncoating or ribonucleoprotein (RNP) export from the nucleus.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Cletoquine

(Desethylhydroxychloroquine)

Cat. No.: HY-135810

Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cletoquine oxalate

(Desethylhydroxychloroquine oxalate)

Cat. No.: HY-135810A

Cletoquine oxalate (Desethylhydroxychloroquine oxalate) is a major active metabolite of Hydroxychloroquine. Cletoquine oxalate is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Cletoquine-d4

(Desethylhydroxychloroquine-d4)

Cat. No.: HY-135810S

Cletoquine-d4 is deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Cletoquine-d4-1

(Desethylhydroxychloroquine-d4-1) Cat. No.: HY-135810S1

Cletoquine-d4-1 (Desethylhydroxychloroquine-d4-1) is the deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clovamide

(trans-Clovamide) Cat. No.: HY-122267

Clovamide (trans-Clovamide), a natural phenolic compound, is a potent antioxidant. Clovamide is an excellent **ROS** and oxygen radical scavenger. Clovamide also has anti-inflammatory and neuroprotective effects.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Coptisine chloride

Cat. No.: HY-N0736

Coptisine chloride is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive **IDO** inhibitor with a K_i value of 5.8 μM and an IC_{50} value of 6.3 μM.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Coumarin

Cat. No.: HY-N0709

Coumarin is the primary bioactive ingredient in Radix Glehniae, named Beishashen in China, which possesses many pharmacological activities, including anticancer, anti-inflammation and antivirus activities.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Coumarin-d4

Cat. No.: HY-N0709S

Coumarin-d4 is the deuterium labeled Coumarin. Coumarin is the primary bioactive ingredient in Radix Glehniae, named Beishashen in China, which possesses many pharmacological activities, including anticancer, anti-inflammation and antivirus activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Crystal Violet

(Basic Violet 3; Gentian Violet; Methyl Violet 10B) Cat. No.: HY-B0324A

Crystal violet (Basic Violet 3) is a triarylmethane dye. Crystal Violet (Gentian Violet) has antiviral effects against **H1N1** and also has prominent bactericidal activities.



Purity: 95.54%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Curcumin

(Diferuloylmethane; Natural Yellow 3; Turmeric yellow) Cat. No.: HY-N0005

Curcumin (Diferuloylmethane), a natural phenolic compound, is a **p300/CREB-binding protein-specific** inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription.



Purity: ≥96.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Curcumin-d6 (Diferuloylmethane-d6; Natural Yellow 3-d6; Turmeric yellow-d6)

Cat. No.: HY-N0005S

Curcumin D6 (Diferuloylmethane D6) is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Cyanidin 3-sambubioside chloride

(Cyanidin-3-O-sambubioside chloride) Cat. No.: HY-N2533

Cyanidin 3-sambubioside chloride (Cyanidin-3-O-sambubioside chloride), a major anthocyanin, a natural colorant, and is a potent **NO** inhibitor.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 5 mg

Cyclofenil

Cat. No.: HY-W011100

Cyclofenil is a selective **estrogen receptor** modulator and an ovulation-inducing agent. Cyclofenil shows an inhibitory effect on **dengue virus** replication in Vero cells with an EC_{50} of 1.62 μM. Cyclofenil has anti-dengue-virus activity.



Purity: ≥95.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Cynarin

(Cynarine) Cat. No.: HY-N0359

Cynarin is an antichoke agent with a variety of biological activities including antioxidant, antihistamic and antiviral activities.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Cynaroside

(Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside) Cat. No.: HY-N0540

Cynaroside (Luteolin 7-glucoside) is a flavone, a flavonoid-like chemical compound. Cynaroside is also a potent **influenza RNA-dependent RNA polymerase** inhibitor with an IC_{50} of 32 nM.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

D-Pinitol

(3-O-Methyl-D-chiro-inositol) Cat. No.: HY-N0655

D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system. D-pinitol has antiviral and larvicidal activities.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Daphnoretin

(Dephnoretin; Thymelol) Cat. No.: HY-N0699

Daphnoretin (Dephnoretin), isolated from Wikstroemia indica, possesses antiviral activity. Daphnoretin likes PMA, may direct activation of protein kinase C which in turn activated NADPH oxidase and elicited respiratory burst.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Dehydroandrographolide

Cat. No.: HY-N0676

Dehydroandrographolide is extracted from herbal medicine Andrographis paniculata Nees. Dehydroandrographolide reduces oxidative stress in LPS-induced acute lung injury by inactivating iNOS. Dehydroandrographolide has anti-infective activity.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Dehydroandrographolide succinate

Cat. No.: HY-N0677

Dehydroandrographolide succinate, extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Dendrobine

Cat. No.: HY-N0638

Dendrobine is an alkaloid isolated from Dendrobium nobile. Dendrobine possesses antiviral activity against **influenza A viruses**, with IC_{50}s of 3.39 μM, 2.16 μM and 5.32 μM for A/FM-1/1/47 (H1N1), A/Puerto Rico/8/34 H274Y (H1N1) and A/Aichi/2/68 (H3N2), respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Desaminotyrosine

(3-(4-Hydroxyphenyl)propionic acid) Cat. No.: HY-W015346

Desaminotyrosine is a microbially associated metabolite protecting from **influenza** through augmentation of **type I interferon** signaling.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Dihydromyricetin

(Ampelopsin; Ampeloptin) Cat. No.: HY-N0112

Dihydromyricetin is a potent inhibitor with an IC_{50} of 48 μM on **dihydropyrimidinase**. Dihydromyricetin can activate autophagy through inhibiting **mTOR** signaling. Dihydromyricetin suppresses the formation of mTOR complexes (**mTORC1/2**).



Purity: 99.79%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Diphyllin

Cat. No.: HY-N2532

Diphyllin is an arylnaphthalene lignan isolated from Justicia procumbens and is a potent **HIV-1** inhibitor with an IC50 of 0.38 μM. Diphyllin is active against **vesicular stomatitis virus (VSV)** and **influenza virus**.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Dryocrassin ABBA

(Dryocrassin)

Cat. No.: HY-N0530

Dryocrassin ABBA (Dryocrassin) is a flavonoid natural product derived from Dryopteris crassirhizoma, with antiviral and antibacterial activities. Dryocrassin ABBA exhibits antiviral activity against **H5N1** avian influenza virus.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

EHNA hydrochloride

Cat. No.: HY-103160A

EHNA hydrochloride is a potent and selective dual inhibitor of **cyclic nucleotide phosphodiesterase 2 (PDE2)**(IC_{50}=4 μM) and **adenosine deaminase (ADA)**.



Relative stereochemistry

Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg

Elemicin

Cat. No.: HY-N6807

Elemicin is a alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits **Stearoyl-CoA Desaturase 1 (SCD1)** by metabolic activation. Elemicin is one of the main components in aromatic food and has antimicrobial, antioxidant, and antiviral activities.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 5 mg

Eleutheroside B1

Cat. No.: HY-135646

Eleutheroside B1, a coumarin compound, has a wide spectrum of anti-human **influenza virus** efficacy, with an IC_{50} value of 64-125 μg/ml. Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Emricasan

(PF 03491390; IDN-6556)

Cat. No.: HY-10396

Emricasan (PF 03491390) is an orally active and irreversible **pan-caspase** inhibitor. Emricasan inhibits **Zika virus (ZIKV)**-induced increases in **caspase-3** activity and protected human cortical neural progenitors.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Epigoitrin

Cat. No.: HY-N0224

Epigoitrin is a natural alkaloid from Isatis indigotica, with antiviral activities. Epigoitrin reduces susceptibility to influenza virus via mitochondrial antiviral signaling.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Eriodictyol

(Huazhongilexone)

Cat. No.: HY-N0637

Eriodictyol is a flavonoid isolated from the Chinese herb, with antioxidant and anti-inflammatory activity. Eriodictyol induces **Nrf2** signaling pathway. Eriodictyol is also a potent **influenza RNA-dependent RNA polymerase** inhibitor with an IC_{50} of 18 nM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Ermanin

Cat. No.: HY-N3848

Ermanin is a flavonoid isolated from Tanacetum microphyllum. Ermanin potently inhibits **iNOS**, **COX-2** activities, and inhibits platelet aggregation. Ermanin has anti-inflammatory, anti-tuberculous and anti-viral/bacterial properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Favipiravir

(T-705)

Cat. No.: HY-14768

Favipiravir (T-705) is a potent viral **RNA polymerase** inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP).



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FGI-106

Cat. No.: HY-124618

FGI-106 is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 is active against **Ebola**, **Rift Valley** and **Dengue Fever viruses** with EC_{50}s of 100 nM, 800 nM and 400-900 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGI-106 tetrahydrochloride

Cat. No.: HY-124618A

FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against **Ebola**, **Rift Valley** and **Dengue Fever viruses** with EC_{50}s of 100 nM, 800 nM and 400-900 nM, respectively.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ganoderic acid TR

Cat. No.: HY-129150

Ganoderic acid TR is a broad-spectrum inhibitor against **influenza neuraminidases (NAs)**, particularly H5N1 and H1N1 neuraminidases. The IC_{50} values of 10.9 and 4.6 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Geldanamycin

Cat. No.: HY-15230

Geldanamycin is a **Hsp90** inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus **H5N1** activities.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Geniposide

Cat. No.: HY-N0009

Geniposide is an iridoid glucoside extracted from Gardenia jasminoides Ellis fruits; exhibits a varity of biological activities such as anti-diabetic, antioxidative, antiproliferative and neuroprotective activities.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Germacrone

Cat. No.: HY-N0440

Germacrone is extracted from Rhizoma Curcuma. Germacrone inhibits **influenza virus** infection.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Ginsenoside Rb2

(Ginsenoside C)

Cat. No.: HY-N0040

Ginsenoside Rb2 is one of the main bioactive components of ginseng extracts. Rb2 can upregulate **GPR120** gene expression. Ginsenoside Rb2 has antiviral effects.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Glabranine

Cat. No.: HY-N3942

Glabranine, an flavonoid, is isolated from Tephrosia s.p, exerts a inhibitory effect in vitro on the dengue virus. Glabranine forms interaction with the soluble ectodomain of DENV type 2 (**DENV2**) E protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Glaucine

(O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396)

Cat. No.: HY-N3945

Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum Crantz with antitussive, bronchodilation and anti-inflammatory properties.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Glaucine-d6 (O,O-Dimethylisoboldine-d6; S-(+)-Glaucine-d6; NSC 34396-d6)

Cat. No.: HY-N3945S

Glaucine-d6 (O,O-Dimethylisoboldine-d6) is the deuterium labeled Glaucine. Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum Crantz with antitussive, bronchodilation and anti-inflammatory properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glycitin

(Glycitein 7-O-β-glucoside)

Cat. No.: HY-N0012

Glycitin is a natural isoflavone isolated from legumes; promotes the proliferation of bone marrow stromal cells and osteoblasts and suppresses bone turnover.Glycitin is antibacterial, antiviral and estrogenic.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Go6976

Cat. No.: HY-10183

Go6976 is a Protein Kinase C (**PKC**) inhibitor, with an IC_{50} of 20 nM.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Goitrin

((S)-Goitrin; L-5-Vinyl-2-thiooxazolidone) Cat. No.: HY-N0224A

Goitrin ((S)-Goitrin), a product of glucosinolate-myrosinase reactions, is a potent inhibitor of **thyroid peroxidase**. Goitrin can inhibit iodine utilization by the thyroid. Goitrin also exhibits anti-influenza virus (**H1N1**) activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

GSK 650394

Cat. No.: HY-15192

GSK 650394 is a novel **SGK** inhibitor with IC_{50} of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits **influenza virus** replication.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Haemanthamine

Cat. No.: HY-114489A

Haemanthamine is a crinine-type alkaloid isolated from the Amaryllidaceae plants with potent anticancer activity. Haemanthamine targets ribosomal that inhibits protein biosynthesis during the elongation stage of translation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Haemanthamine hydrochloride

Cat. No.: HY-114489B

Haemanthamine hydrochloride is a crinine-type alkaloid isolated from the Amaryllidaceae plants with potent anticancer activity. Haemanthamine hydrochloride targets ribosomal that inhibits protein biosynthesis during the elongation stage of translation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Harringtonine

Cat. No.: HY-N0862

Harringtonine is a natural Cephalotaxus alkaloid that inhibits **protein synthesis**. Harringtonine has anti-**chikungunya virus (CHIKV)** activities with an EC_{50} of 0.24 μM.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

hDHODH-IN-3

Cat. No.: HY-135570

hDHODH-IN-3 (compound 21d) is a **human dihydroorotate dehydrogenase (HsDHODH)** inhibitor, inhibits measles virus replication with a $pMIC_{50}$ value of 8.6.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

hDHODH-IN-4

Cat. No.: HY-128787

hDHODH-IN-4 is a potent human **dihydroorotate dehydrogenase (DHODH)** inhibitor, with a pIC_{50} of 7.8 for human recombinant DHODH. hDHODH-IN-4 inhibits measles virus replication, with a $pMIC_{50}$ of 8.8.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

hDHODH-IN-7

Cat. No.: HY-135667

DHODH-IN-9 (Compound 10k) is an azine-bearing analogue and is a **human dihydroorotate dehydrogenase** inhibitor. DHODH-IN-9 has antiviral effect with a $pMIC_{50}$ of 7.4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Herquline A

(Herqueline A) Cat. No.: HY-125705

Herquline A (Herqueline A) is a fungal piperazine alkaloid. Herquline A is a fungal metabolite that inhibits platelet aggregation and replication of the influenza virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hesperadin

Cat. No.: HY-12054

Hesperadin is an ATP competitive indolinone inhibitor of **Aurora A** and **B**. Hesperadin inhibits Aurora B with an IC_{50} of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hesperadin hydrochloride

Cat. No.: HY-12054A

Hesperadin hydrochloride is an ATP competitive indolinone inhibitor of **Aurora A** and **B**. Hesperadin hydrochloride inhibits Aurora B with an IC_{50} of 250 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hypericin

Cat. No.: HY-N0453

Hypericin is a photosensitive antiviral with anticancer and antidepressant agent derived from Hypericum perforatum. It can inhibit tyrosine kinases with IC50 of 7.5 μM.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Hypericin-d10

Cat. No.: HY-N0453S

Hypericin-d10 is the deuterium labeled Hypericin. Hypericin is a photosensitive antiviral with anticancer and antidepressant agent derived from Hypericum perforatum. It can inhibit tyrosine kinases with IC_{50} of 7.5 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hypericin-d2

Cat. No.: HY-N0453S1

Hypericin-d2 is deuterium labeled Hypericin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hyperoside

Cat. No.: HY-N0452

Hyperoside, a natural flavonoid, isolated from Camptotheca acuminate, possesses antifungal, anti-inflammatory, anti-viral, anti-oxidative and anti-apoptotic activities.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

IHVR-17028

Cat. No.: HY-139663

IHVR-17028 is a potent and broad-spectrum **antiviral** agent. IHVR-17028 exhibits antiviral activity against BVDV, TCRV and DENV with EC_{50} values of 0.4 μM, 0.26 μM, 0.3 μM, respectively. IHVR-17028 is a potent ER **α-glucosidase I** inhibitor with an IC_{50} of 0.24 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza A NP(366-374) Strain A/PR/8/35

Cat. No.: HY-P1788

Influenza A NP(366-374) Strain A/PR/8/35 is an H2-Db-restricted epitope from Influenza A/PR/8/35 nucleoprotein.

ASNENMETM

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza A virus-IN-1

Cat. No.: HY-131179

Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of **influenza A virus (IAV)** with IC_{50} values from 3.11 μM to 7.13 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza A virus-IN-4

Cat. No.: HY-146004

Influenza A virus-IN-4 (compound 23b), an Oseltamivir derivative, is a potent inhibitor of **neuraminidase**. Influenza A virus-IN-4 exerts powerful inhibitions on influenza viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza A virus-IN-6

Cat. No.: HY-146360

Influenza A virus-IN-6 (compound 16j) is a potent and selective **influenza A virus** inhibitor with an IC_{50} of 3.88 μM and CC_{50} of 36.64 μM. Influenza A virus-IN-6 shows anti-IAV activity with low cytotoxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza A virus-IN-7

Cat. No.: HY-146361

Influenza A virus-IN-7 (compound 16r) is a potent and orally active **influenza A virus** inhibitor with an IC_{50} of 3.43 μM and CC_{50} of >100 μM. Influenza A virus-IN-7 shows anti-IAV activity with low cytotoxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza HA (307-319)

Cat. No.: HY-P1749

Influenza HA (307-319) is 13 amino acids 307 to 319 fragment of Influenza HA. Influenza HA is a glycoprotein found on the surface of influenza viruses.

PKYVKQNTLKLAT

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza NP (147-155)

Cat. No.: HY-P1762

Influenza NP (147-155) is a K^d restricted epitope from influenza nucleoprotein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza NP (147-155) (TFA)

Cat. No.: HY-P1762A

Influenza NP (147-155) TFA is a K^d restricted epitope from influenza nucleoprotein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza virus-IN-1

Cat. No.: HY-143492

Influenza virus-IN-1 (compound 14) is a potent **influenza A virus** inhibitor with an EC_{50} of 2.46 μM and CC_{50} of >200 μM. Influenza virus-IN-1 shows a concentration dependent inhibition activity for PA_N endonuclease with EC_{50} of 312.36 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza virus-IN-2

Cat. No.: HY-143493

Influenza virus-IN-2 (compound 19) is a potent **influenza virus** inhibitor with an EC_{50} of 2.58 μM and CC_{50} of 150.85 μM. Influenza virus-IN-2 shows a concentration dependent inhibition activity for PA_N endonuclease with EC_{50} of 489.39 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza virus-IN-3

Cat. No.: HY-146000

Influenza virus-IN-3 (compound 9) is a potent and selective **influenza virus** inhibitor with IC_{50}s of 0.88, 0.10, 5.5, 0.51 μM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-3 shows antiviral and NA (neuraminidase enzyme)-inhibitory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Influenza virus-IN-4

Cat. No.: HY-146001

Influenza virus-IN-4 (compound 11e) is a potent **influenza virus neuraminidase** inhibitor with IC_{50}s of 3.4, 0.094, 0.79, 0.077 μM for H5N1, H5N2, H5N6, H5N8, respectively. Influenza virus-IN-4 shows NA (neuraminidase enzyme)-inhibitory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iniparib

(BSI-201; NSC-746045; IND-71677)

Cat. No.: HY-12015

Iniparib (BSI-201) is an irreversible inhibitor of **PARP1**, used in the research of triple negative breast cancer.



Purity: 99.87%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Isoferulic acid

(3-Hydroxy-4-methoxycinnamic acid)

Cat. No.: HY-N0761

Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is a cinnamic acid derivative that has antidiabetic activity. Isoferulic acid binds to and activates α1-adrenergic receptors (IC_{50}=1.4 μM) to enhance secretion of β-endorphin (EC_{50}=52.2 nM) and increase glucose use.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Isoliquiritigenin

(GU17; ISL; Isoliquiritigen)

Cat. No.: HY-N0102

Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza glabra, which inhibits **aldose reductase** with an **IC_{50}** of 320 nM. Isoliquiritigenin is a potent inhibitor of **influenza virus** replication with an **EC_{50}** of 24.7 μM.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Isomangiferin

Cat. No.: HY-N0772

Isomangiferin, a natural product, is reported to have antiviral activity.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

JNJ4796

Cat. No.: HY-122907

JNJ4796 is an oral active fusion inhibitor of **influenza virus**, neutralizing influenza A group 1 viruses by inhibiting **hemagglutinin (HA)**-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs).



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Kaempferide

(Kaempferol 4'-O-methyl ether)

Cat. No.: HY-15449

Kaempferide is an O-methylated flavonol, a type of chemical compound. It can be found in Kaempferia galanga (aromatic ginger).



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

KIN101

Cat. No.: HY-126113

KIN101 is a potent **RNA viral** inhibitor with **IC_{50}**s of 2 μM, >5 μM for **influenza virus** and Dengue virus (DNV), respectively. KIN101, an isoflavone agonist of **IRF-3** dependent signaling, induces IRF-3 nuclear translocation. KIN101 has broad-spectrum activity against RNA viruses.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

KIN1148

Cat. No.: HY-101950

KIN1148, a small-molecule **IRF3** agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

KIN1408

Cat. No.: HY-19961

KIN1408 is an agonist of the **RIG-1-like receptor (RLR) pathway** and exhibits a broad-spectrum antiviral activity. KIN1408 exhibits activity against **HCV**, **influenza A**, **dengue virus 2**, **Ebola**, **Nipah**, and **Lassa viruses**.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-Norleucine

((S)-2-Aminohexanoic acid; (S)-Norleucine)

Cat. No.: HY-Y0017

L-Norleucine ((S)-2-Aminohexanoic acid) is an isomer of leucine, specifically affects protein synthesis in skeletal muscle, and has antivirus activity.



Purity: ≥97.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 500 mg, 1 g

L-Norleucine-d9

((S)-2-Aminohexanoic acid-d9; (S)-Norleucine-d9)

Cat. No.: HY-Y0017S

L-Norleucine-d9 ((S)-2-Aminohexanoic acid-d9) is the deuterium labeled L-Norleucine. L-Norleucine ((S)-2-Aminohexanoic acid) is an isomer of leucine, specifically affects protein synthesis in skeletal muscle, and has antivirus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lactimidomycin

Cat. No.: HY-18979

Lactimidomycin is a glutarimide-containing compound isolated from Streptomyces. Lactimidomycin is a potent inhibitor of **eukaryotic translation elongation**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 200 μg

Laninamivir

(R 125489)

Cat. No.: HY-14818

Laninamivir (R 125489) is a potent influenza **neuraminidase (NA)** inhibitor with IC_{50}s of 0.90 nM, 1.83 nM and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Laninamivir octanoate

(CS-8958)

Cat. No.: HY-14818A

Laninamivir octanoate (CS-8958), a prodrug of Laninamivir, is a long-acting **neuraminidase (NA)** inhibitor with anti-influenza virus activity.



Purity: 98.06%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Laninamivir octanoate-d3

(CS-8958-d3)

Cat. No.: HY-14818AS

Laninamivir octanoate-d3 (CS-8958-d3) is the deuterium labeled Laninamivir octanoate. Laninamivir octanoate (CS-8958), a prodrug of Laninamivir, is a long-acting **neuraminidase (NA)** inhibitor with anti-influenza virus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Laninamivir-d3

Cat. No.: HY-14818S

Laninamivir-d3 (R 125489-d3) is the deuterium labeled Laninamivir. Laninamivir (R 125489) is a potent influenza **neuraminidase (NA)** inhibitor with IC_{50}s of 0.90 nM, 1.83 nM and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 250 μg

Lapachol

Cat. No.: HY-N6961

Lapachol is a naphthoquinone that was first isolated from Tabebuia avellanedae (Bignoniaceae).



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Loratadine

(Loratidine; SCH 29851)

Cat. No.: HY-17043

Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-**dengue-virus (DENV)** activity. Loratadine can inhibit immunologic release of inflammatory mediators.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Loratadine-d4

(Loratidine-d4; SCH 29851-d4)

Cat. No.: HY-17043S

Loratadine-d4 (Loratidine-d4) is the deuterium labeled Loratadine. Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-**dengue-virus (DENV)** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Loratadine-d5

(Loratidine-d5; SCH 29851-d5)

Cat. No.: HY-17043S1

Loratadine-d5 (Loratidine-d5) is the deuterium labeled Loratadine. Loratadine (SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM. Loratadine has anti-**dengue-virus (DENV)** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Loxoribine

(7-Allyl-8-oxoguanosine; RWJ 21757)

Cat. No.: HY-108472

Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective **Toll-like receptor (TLR) 7** agonist.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

M2 ion channel blocker

Cat. No.: HY-75867

M2 ion channel blocker is capable of inhibiting and blocking the activity of M2 ion channel;Antiviral agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

M2e, human

Cat. No.: HY-P1783

M2e, human, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A, which is a valid and versatile vaccine candidate to protect against any strain of human influenza A.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

M2e, human TFA

Cat. No.: HY-P1783A

M2e, human TFA, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A. M2e, human TFA is a valid and versatile vaccine candidate to protect against any strain of human influenza A.

Purity: 99.37%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Massarilactone H

Cat. No.: HY-N10298

Massarilactone H, a polyketide, is a **neuraminidase** inhibitor, with an IC_{50} of 8.18 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MBX2329

Cat. No.: HY-131069A

MBX2329, a potent **influenza virus** inhibitor, specifically inhibits hemagglutinin (HA)-mediated viral entry with HIV/HA(H5) displaying IC_{90} of 8.6 μM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

ML303

Cat. No.: HY-126136

ML303 is a pyrazolopyridine **influenza virus nonstructural protein 1 (NS1)** antagonist (IC_{90} = 155 nM), with an EC_{50} of 0.7 μM for Influenza A virus H1N1.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Molnupiravir

(EIDD-2801; MK-4482)

Cat. No.: HY-135853

Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against **influenza virus** and multiple **coronaviruses**, such as **SARS-CoV-2**, **MERS-CoV**, **SARS-CoV**.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Moroxydine hydrochloride

(ABOB hydrochloride)

Cat. No.: HY-B0420A

Moroxydine hydrochloride (ABOB hydrochloride) is a synthetic antiviral compound chemically belonging to the series of the heterocyclic biguanidines.



Purity: 99.57%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g, 10 g

N-Acetylneuraminic acid

(NANA; Lactaminic acid)

Cat. No.: HY-I0400

N-Acetylneuraminic acid is a nine-carbon, sialic acid monosaccharide commonly found in glycoproteins on cell membranes and in glycolipids such as gangliosides in mammalian cells.



Purity: ≥95.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg, 1 g

N-Glycolylneuraminic acid

(NeuGc; GcNeu)

Cat. No.: HY-128965

N-Glycolylneuraminic acid is a nonhuman sialic acid molecule synthesized in pigs but not in humans. N-Glycolylneuraminic acid works as a decoy receptor of N-Glycolylneuraminic acid-binding **influenza A viruses (IAVs)**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

N6-Methyladenosine

(6-Methyladenosine; N-Methyladenosine) Cat. No.: HY-N0086

N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies **viral RNAs** and has antiviral activities.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Naringenin

Cat. No.: HY-N0100

Naringenin is the predominant flavanone in grapefruit; displays strong anti-inflammatory and antioxidant activities. Naringenin has anti-**dengue virus (DENV)** activity.



Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Netropsin dihydrochloride

Cat. No.: HY-N6800A

Netropsin (dihydrochloride) is a small-molecule MGB (minor-groove binder), inhibits the catalytic activity of isolated topoisomerase and interferes with the stabilization of the cleavable complexes of topoisomerase II and I in nuclei.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg

Neuraminidase-IN-1

Cat. No.: HY-137334

Neuraminidase-IN-1 is a **neuraminidase** inhibitor, with an IC_{50} of 0.21 μM. Neuraminidase-IN-1 has excellent activity against **H1N1 influenza virus**.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Neuraminidase-IN-3

Cat. No.: HY-139991

Neuraminidase-IN-3 (compound 23d) is a potent influenza **neuraminidase (NA)** inhibitor with IC_{50} values of 0.73, 0.26, and 0.63 nM against H1N1, H5N1, and H5N8 NAs, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuraminidase-IN-4

Cat. No.: HY-144103

Neuraminidase-IN-4 (Compound 4b) is a potent inhibitor of **neuraminidase** with an EC_{50} of 1.59 μM. Neuraminidase (NA) is an important target for the treatment of influenza. Neuraminidase-IN-4 exhibits excellent antiviral activity against A/chicken/Hubei/327/2004 (H5N1-DW).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuraminidase-IN-5

Cat. No.: HY-144420

Neuraminidase-IN-5 (Compound 5b) is a potent inhibitor of **neuraminidase** with an IC_{50} of 0.02 μM. Neuraminidase (NA) is a promising target for development of anti-influenza drugs. Neuraminidase-IN-5 is a dihydrofurocoumarin derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuraminidase-IN-6

Cat. No.: HY-144426

Neuraminidase-IN-6 (Compound 5c) is a potent inhibitor of **neuraminidase** with an IC_{50} of 0.11 μM. Neuraminidase-IN-6 is a 1,3,4-triazole-3-acetamide derivative. Neuraminidase (NA) is an ideal target for the development of anti-influenza drugs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuraminidase-IN-7

Cat. No.: HY-143453

Neuraminidase-IN-7 (compound 4b), a thiophene derivative, is a potent **neuraminidase** inhibitor with an IC_{50} of 0.03 μM. Neuraminidase-IN-7 also exhibits excellent antiviral activity against A/chicken/Hubei/327/2004 (H5N1-DW) (EC_{50}=1.59 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuraminidase-IN-8

Cat. No.: HY-143488

Neuraminidase-IN-8 (Compound 6d) is a potent **neuraminidase** inhibitor with an IC_{50} of 0.027 μM. Neuraminidase-IN-8 shows anti-influenza activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Neuraminidase-IN-9

Cat. No.: HY-146306

Neuraminidase-IN-9 (Compound 6l) is a potent influenza **neuraminidase** inhibitor with IC_{50} values of 0.12, 0.049 and 0.16 μM against **H5N1**, **H5N2** and **H5N6**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nimbin

Cat. No.: HY-N3187

Nimbin is a intermediate limonoid isolated from Azadirachta. Nimbin prevents **tau** aggregation and increases cell viability. Nimbin is effective inhibits the **envelope protein of dengue virus**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nitazoxanide

(NTZ; NSC 697855)

Cat. No.: HY-B0217

Nitazoxanide (NTZ), an **anthelmintic** agent, exhibits a broad spectrum of activities against a wide variety of helminths, protozoa, and enteric bacteria infecting animals and humans.



Purity: 98.35%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Nitazoxanide-d4

(NTZ-d4; NSC-697855-d4)

Cat. No.: HY-B0217S

Nitazoxanide D4 (NTZ D4) is the deuterium labeled Nitazoxanide, which is an antiprotozoal agent.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

NITD008

(7-Deaza-2'-C-acetylene-adenosine)

Cat. No.: HY-12957

NITD008 is a potent and selective **flaviviruse** inhibitor which can inhibit **Dengue Virus Type 2 (DENV-2)** with an EC_{50} of 0.64 μM.



Purity: 96.58%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nonactin

(Ammonium ionophore I)

Cat. No.: HY-N6790

Nonactin is a naturally occurring macrotetrolide antibiotic from Streptomyces griseus. Nonactin acts as an ionophore for monovalent cations, including **K^+, and NH_4^+**. Nonactin is able to uncouple the oxidative phosphorylation (**OXPHOS**) of mitochondria.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Nucleozin

Cat. No.: HY-50001

Nucleozin, a potent inhibitor of **influenza A virus** infection, induces the formation of nucleoprotein (NP) aggregates and antagonizes its nuclear accumulation, leading to cessation of viral replication. Nucleozin impedes influenza A virus replication in vitro with a nanomolar EC_{50}.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Octaethylene glycol monododecyl ether

(C12E8)

Cat. No.: HY-138941

Octaethylene glycol monododecyl ether (C12E8) is an non-ionic detergent that can be used for membrane protein extraction. Octaethylene glycol monododecyl ether can solubilize the viral membrane of intact **influenza virus**.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 50 mg

Octyl gallate

(n-Octyl gallate; Stabilizer GA 8)

Cat. No.: HY-N2011

Octyl gallate (Progallin O) is widely used as a food additive, with antimicrobial and antioxidant activity. Octyl gallate (Progallin O) shows selective and sensitive fluorescent property.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Onradivir

Cat. No.: HY-145586

Onradivir is a significantly better anti-influenza virus agent extracted from patent WO2021047437 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oseltamivir acid

(GS 4071; Ro 64-0802; Oseltamivir carboxylate) Cat. No.: HY-13318

Oseltamivir acid (GS 4071), the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of **influenza virus neuraminidase (IC_{50}=2 nM)** with activity against both influenza A and B viruses.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Oseltamivir acid-d3

(GS 4071-d3; Ro 64-0802-d3; Oseltamivir carboxylate-d3) Cat. No.: HY-13318S

Oseltamivir acid D3 (GS 4071 D3) is a deuterium labeled Oseltamivir acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Oseltamivir phosphate

(GS 4104) Cat. No.: HY-17016

Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of **influenza A** and **B**.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Oseltamivir-acetate

Cat. No.: HY-43575

Oseltamivir-acetate is an impurity of Oseltamivir. Oseltamivir is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 25 mg

Oseltamivir-d3

Cat. No.: HY-13317S

Oseltamivir D3 is a deuterium labeled Oseltamivir. Oseltamivir is an **influenza virus neuraminidase** inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC_{50}s of 0.67, 0.9, 1.34 and 13 nM, respectively. Anti-influenza A and B agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oseltamivir-d3 phosphate

(GS 4104-d3 phosphate) Cat. No.: HY-17016S1

Oseltamivir-d3 (GS 4104-d3) phosphateis the deuterium labeled Oseltamivir phosphate. Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of **influenza A** and **B**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oseltamivir-d5 phosphate

(GS 4104-d5) Cat. No.: HY-17016S

Oseltamivir-d5 phosphate (GS 4104-d5) is the deuterium labeled Oseltamivir phosphate. Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of **influenza A** and **B**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oxymatrine

Cat. No.: HY-N0158

Oxymatrine, an alkaloid from the roots of Sophora species, with anti-inflammatory, antifibrosis, and antitumor effects, inhibits the **iNOS** expression and **TGF-β/Smad** pathway.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g

PA (224-233), Influenza

Cat. No.: HY-P1580

PA (224-233), Influenza is a 10-aa peptide, a fragment of polymerase 2 protein in influenza A virus.

SSLENFRAYV

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Palmitoylethanolamide

(Palmidrol; Loramine P 256) Cat. No.: HY-20685

Palmitoylethanolamide (Palmidrol) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Palmitoylethanolamide-d4

(Palmidrol-d4; Loramine P 256-d4) Cat. No.: HY-20685S

Palmitoylethanolamide-d4 (Palmidrol-d4) is the deuterium labeled Palmitoylethanolamide. Palmitoylethanolamide (Palmidrol) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Peramivir

(RWJ-270201; BCX-1812) Cat. No.: HY-17015A

Peramivir (RWJ-270201;BCX-1812) is a highly potent, selective and orally active influenza virus **neuraminidase (NA)** inhibitor, with **IC_{50}** values ranging form 0.9 to 4.3 nM for nine NA subtypes.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Peramivir trihydrate

(RWJ 270201 trihydrate; BCX 1812 trihydrate) Cat. No.: HY-17015

Peramivir trihydrate (RWJ-270201 trihydrate;BCX-1812 trihydrate) is a highly potent, selective and orally active influenza virus **neuraminidase (NA)** inhibitor, with **IC_{50}** values ranging from 0.9 to 4.3 nM for nine NA subtypes.



Purity: 99.53%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Phillyrin

Cat. No.: HY-N0482

Phillyrin is isolated from Forsythia suspensa Vahl (Oleaceae), has antibacterial and anti-inflammatory activities. Phillyrin has potential inductive effects on rat **CYP1A2** and **CYP2D1** activities, without affecting CYP2C11 and CYP3A1/2 activities.



Purity: 98.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Picroside II

Cat. No.: HY-N0408

Picroside II, an iridoid compound extracted from Picrorhiza, exhibits anti-inflammatory and anti-apoptotic activities. picroside II alleviates the inflammatory response in sepsis and enhances immune function by inhibiting the activation of **NLRP3** inflammasome and **NF-κB** pathways.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pimodivir

(VX-787) Cat. No.: HY-12353A

Pimodivir (VX-787) is an orally bioavailable inhibitor of **influenza A virus polymerases** through interaction with the viral **PB2** subunit.



Purity: 99.45%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Polygalasaponin XXXI

(Onjisaponin F) Cat. No.: HY-N2216

Polygalasaponin XXXI (Onjisaponin F) is an effective adjuvant for intranasal administration of influenza Influenza hemagglutinin (HA) vaccine to protect influenza virus infection.



Purity: 96.19%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PP7

Cat. No.: HY-100858

PP7 is a potent PB1-PB2 interaction inhibitor with an **IC_{50}** of 8.6 μM, and their inhibition against viral polymerase activity (**IC_{50}**=9.5 μM). PP7 shows antiviral activities against influenza A virus (IAV), including A(H1N1)pdm09 (**EC_{50}**=1.4 μM), A(H7N9) and A(H9N2) subtypes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Psoralen

(Ficusin) Cat. No.: HY-N0053

Psoralen (Ficusin) is a coumarin isolated from the seeds of Fructus Psoraleae. Psoralen exhibits a wide range of biological properties, including anti-cancer, antioxidant, antidepressant, anticancer, antibacterial, and antiviral, et al.



Purity: 99.92%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

QL-X-138

Cat. No.: HY-124645

QL-X-138 is a potent and selective **BTK/MNK dual kinase** inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows **IC_{50}**s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RdRP-IN-4

Cat. No.: HY-144668

RdRP-IN-4 (compound 11q), an aryl benzoyl hydrazide analog, is an orally active **influenza A virus RNA-dependent RNA polymerase (RdRp)** inhibitor by interacting with the PB1 subunit.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rifampicin

(Rifampin; Rifamycin AMP)

Cat. No.: HY-B0272

Rifampicin is a potent and broad spectrum antibiotic against **bacterial** pathogens. Rifampicin has anti-**influenza virus** activities.



Purity: 98.15%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Rifampicin-d3

Cat. No.: HY-B0272S

Rifampicin-d3 (Rifampin-d3) is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against **bacterial** pathogens. Rifampicin has anti-**influenza virus** activities.



Purity: >98%
Clinical Data:
Size: 500 µg, 5 mg

Rifampicin-d4

(Rifampin-d4; Rifamycin AMP-d4)

Cat. No.: HY-B0272S2

Rifampicin-d4 (Rifampin-d4) is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against **bacterial** pathogens. Rifampicin has anti-**influenza virus** activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RIG-1 modulator 1

Cat. No.: HY-107902

RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including **influenza virus**, **HBV**, **HCV** and **HIV** extracted from patent WO 2015172099 A1.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Rimantadine

(1-Rimantadine)

Cat. No.: HY-B0338

Rimantadine (Flumadine) is an anti-influenza virus drug. Target: Influenza Virus rimantadine are oral antiviral drugs useful in the prophylaxis and treatment of influenza A virus infections.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Rimantadine hydrochloride

Cat. No.: HY-B0338A

Rimantadine hydrochloride is an anti-influenza virus drug. Target: Influenza Virus Rimantadine hydrochloride are oral antiviral drugs useful in the prophylaxis and treatment of influenza A virus infections.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g

Rimantadine-d4 hydrochloride

Cat. No.: HY-B0338S

Rimantadine-d4 hydrochloride is the deuterium labeled Rimantadine hydrochloride. Rimantadine hydrochloride is an anti-influenza virus agent.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 1 mg, 5 mg

RO-7

Cat. No.: HY-112684

RO-7 is a next-generation polymerase (PA) endonuclease inhibitor of influenza A and B viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rose Bengal sodium

Cat. No.: HY-D0214

Rose Bengal sodium, a synthetic fluorescein derivative, and is a crimson-coloured dye with the principal component being 4,5,6,7-tetrachloro-2,4,5,7-tetraiodo fluorescein.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mg

RSV/IAV-IN-1

Cat. No.: HY-130626

RSV/IAV-IN-1 (compound 14e) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-1 has lesser cytotoxicity than the clinical drug, Ribavirin. RSV/IAV-IN-1 has the potential for the research of RSV and/or IAV infections.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RSV/IAV-IN-2

Cat. No.: HY-130627

RSV/IAV-IN-2 (compound 14c) is a potent and dual inhibitor of RSV/IAV. RSV/IAV-IN-2 has lesser cytotoxicity than the clinical drug, Ribavirin. RSV/IAV-IN-2 has the potential for the research of RSV and/or IAV infections.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RSV/IAV-IN-3

Cat. No.: HY-143494

RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of **respiratory syncytial virus (RSV)** and **influenza A virus (IAV)** with EC_{50} values of 2.92 μM and 1.90 μM,respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rupestonic acid

Cat. No.: HY-N3016

Rupestonic acid, a sesquiterpene, can inhibit **influenza virus**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

S119-8

Cat. No.: HY-112543

S119-8 is a broad spectrum inhibitor of influenza A and B viruses, showing activity against multiple influenza B viruses and an oseltamivir-resistant influenza A virus, but does not inhibit a non-influenza virus, vesicular stomatitis nirus (VSV).



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC75741

Cat. No.: HY-10496

SC75741 is a broad and efficient **NF-κB** inhibitor with an IC_{50} of 200 nM for **p65**. SC75741 blocks **influenza viruses (IV)** replication. SC75741 impairs DNA binding of the **NF-κB** subunit p65, resulting in reduced expression of cytokines, chemokines, and pro-apoptotic factors.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Scriptaid

(Scriptide; GCK1026)

Cat. No.: HY-15489

Scriptaid is a potent **histone deacetylase (HDAC)** inhibitor, used in cancer research. Scriptaid is also a sensitizer to antivirals and has potential for epstein-barr virus (EBV)-associated lymphomas treatment.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Sodium copper chlorophyllin B

Cat. No.: HY-B2226

Sodium copper chlorophyllin B exerts **antiviral** activities against **Influenza virus** and **HIV** with IC_{50}s of 50 to 100 μM for both of them.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Sophocarpine

Cat. No.: HY-N0103

Sophocarpine is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Sophocarpine monohydrate

Cat. No.: HY-N0103A

Sophocarpine (monohydrate) is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Soyasaponin II

Cat. No.: HY-122920

Soyasaponin II is a saponin with antiviral activity. Soyasaponin II inhibits the replication of HSV-1, HCMV, influenza virus, and HIV-1. Soyasaponin II shows potent inhibition on HSV-1 replication.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 1 mg

SP187

(MON-DNJ; UV4)

Cat. No.: HY-U00160

SP187 is a host-targeted iminosugar with activity against filovirus infections in vitro and in vivo. SP187 is active against influenza and dengue in vivo.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Spermine

(NSC 268508; Neuridine)

Cat. No.: HY-B1777

Spermine (NSC 268508) functions directly as a free radical scabenger to protect DNA from free radical attack. Spermine has antiviral effects.

Purity: 98.36%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 100 mg

T-1105

Cat. No.: HY-W015764

T-1105, a novel broad-spectrum viral **polymerase** inhibitor, structural analogue of T-705, inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite.



Purity: 96.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Tenuazonic acid

Cat. No.: HY-N6715

Tenuazonic acid, belonging to tetramic acids that are the largest family of natural products, is a putative nonhost-selective mycotoxin isolated from Alternaria alternate.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tetrahydroepiberberine

Cat. No.: HY-N3035

Tetrahydroepiberberine is a isoquinoline alkaloid isolated from Corydalis impatiens (Pall). Tetrahydroepiberberine has **antifungal** and selective inhibition against the **PI-3 virus** activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Theaflavin

Cat. No.: HY-N0243

Theaflavin is a suitable natural inhibitor against influenza A (**H1N1**) neuraminidase.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Tilorone dihydrochloride

Cat. No.: HY-B1080

Tilorone dihydrochloride is the first recognized synthetic, small molecular weight compound that is an orally active interferon inducer, used as an antiviral drug.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Tofacitinib citrate

(Tasocitinib citrate; CP-690550 citrate)

Cat. No.: HY-40354A

Tofacitinib citrate is an orally available **JAK1/2/3** inhibitor with IC_{50}s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tofacitinib-d3 citrate

(Tasocitinib-d3 citrate; CP-690550-d3 citrate)

Cat. No.: HY-40354AS

Tofacitinib-d3 (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Triazavirin

Cat. No.: HY-19743

Triazavirin is a nucleoside analogue of nucleic acid and an antiviral agent. Triazavirin works by inhibiting the synthesis of viral RNA and DNA and replication of genomic fragments. Triazavirin is also an effective protective agent on the transmission stage of influenza.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Trimethobenzamide hydrochloride

(Ro 2-9578)

Cat. No.: HY-12751A

Trimethobenzamide hydrochloride is a blocker of the D_2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting.



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Tubercidin

(7-Deazaadenosine)

Cat. No.: HY-100126

Tubercidin (7-Deazaadenosine) is an antibiotic obtained from Streptomyces tubercidicus. Tubercidin inhibits the growth of Streptococcus faecalis (8043) with an IC_{50} of 0.02 μM.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tulobuterol hydrochloride

(C-78)

Cat. No.: HY-W011733

Tulobuterol hydrochloride (C-78) is a long-acting **β_2-adrenoceptor agonist, which reduces the frequency of exacerbations of chronic obstructive pulmonary disease and bronchial asthma.**.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Tunicamycin

Cat. No.: HY-A0098

Tunicamycin is a mixture of homologous nucleoside antibiotic that inhibits **N-linked glycosylation** and blocks **GlcNAc phosphotransferase (GPT)**.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg

Tyrothricin

Cat. No.: HY-120435

Tyrothricin is a polypeptide antibiotic mixture isolated from Bacillus brevis and consists of tyrocidines and gramicidins. Tyrothricin shows activity against **bacteria**, **fungi** and some **viruses**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Tyrphostin A9

(Tyrphostin 9; Malonoben)

Cat. No.: HY-15511

Tyrphostin A9, a **PDGFR** inhibitor, is a potent inducer of mitochondrial fission. Tyrphostin A9 emerged as the most potent and selective of 51 tyrosine kinase inhibitors tested against the TNF-induced respiratory burst. Tyrphostin A9 has **anti-influenza virus** activities.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

U0126

Cat. No.: HY-12031A

U0126 is a potent, non-ATP competitive and selective **MEK1** and **MEK2** inhibitor, with IC_{50}s of 72 nM and 58 nM, respectively. U0126 is an **autophagy** and **mitophagy** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

U0126-EtOH

Cat. No.: HY-12031

U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective **MEK1** and **MEK2** inhibitor, with IC_{50}s of 72 nM and 58 nM, respectively. U0126 is an **autophagy** and **mitophagy** inhibitor.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Umifenovir

Cat. No.: HY-14904

Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an **anti-influenza virus** agent. Umifenovir could effectively inhibit the fusion of virus with host cells.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Umifenovir hydrochloride

Cat. No.: HY-14904A

Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an **anti-influenza virus** agent.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Umifenovir-d6 hydrochloride

Cat. No.: HY-14904AS

Umifenovir-d6 hydrochloride is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC0638

Cat. No.: HY-15273

UNC0638 selectively inhibits **G9a** and **GLP histone methyltransferase** activity with **IC_{50}**s of less than 15 nM and 19 nM, respectively. UNC0638 has anti-**FMDV (foot-and-mouth disease virus)** and anti-**VSV (vesicular stomatitis virus)** activities.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vadimezan

(DMXAA; ASA-404)

Cat. No.: HY-10964

Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the **stimulator of interferon genes** (**STING**) and also a potent inducer of **type I IFNs** and other cytokines. Vadimezan has anti-influenza virus **H1N1-PR8** activities.



Purity: 99.81%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Wulignan A1

Cat. No.: HY-N2264

Wulignan A1 is isolated from the stems of Schisandra henryi. Wulignan A1 exhibits anti-influenza virus **H1N1** and **H1N1-TR** (a Tamiflu drug resistant virus strain) activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Xanthohumol

Cat. No.: HY-N1067

Xanthohumol is one of the principal flavonoids isolated from hops, the inhibitor of diacylglycerol acetyltransferase (**DGAT**), **COX-1** and COX-2, and shows anti-cancer and anti-angiogenic activities.



Purity: 99.84%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Xanthone

Cat. No.: HY-N0126

Xanthone is isolated from Mangosteen and is known to control cell division and growth, apoptosis, inflammation, and metastasis in different stages of carcinogenesis.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 100 mg

Yadanziolide B

Cat. No.: HY-N8399

Yadanziolide B, a natural quassinoid, is a potential **H5N1** neuraminidase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

YM-201636

Cat. No.: HY-13228

YM-201636 is a potent and selective **PIKfyve** inhibitor with an **IC_{50}** of 33 nM. YM-201636 also inhibits p110α with an IC_{50} of 3.3 μM. YM-201636 inhibits **retroviral** replication.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Z-VRPR-FMK TFA

(VRPR)

Cat. No.: HY-P1407

Z-VRPR-FMK (TFA) (VRPR), a tetrapeptide, is a selective and irreversible **MALT1** (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor. Z-VRPR-FMK (TFA) can protect against **influenza A virus (IAV)** infection.



Purity: 95.92%
Clinical Data: No Development Reported
Size: 500 μg

Zanamivir

Cat. No.: HY-13210

Zanamivir is an influenza viral **neuraminidase** inhibitor with IC_{50} values of 0.95 nM and 2.7 nM for influenza A and B, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Zanamivir-Cholesterol Conjugate

Cat. No.: HY-141862

Zanamivir–cholesterol conjugate is a long-acting **neuraminidase** inhibitor with potent efficacy against drug-resistant influenza viruses.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zapnometinib

(PD0184264; ATR-002)

Cat. No.: HY-139558

Zapnometinib (PD0184264), an active metabolite of CI-1040, is a **MEK** inhibitor, with an IC_{50} of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

α-Vitamin E

((+)-α-Tocopherol; D-α-Tocopherol)

Cat. No.: HY-N0683

α-Vitamin E ((+)-α-Tocopherol), a naturally occurring vitamin E form, is a potent antioxidant.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g

α-Vitamin E-13C3

((+)-α-Tocopherol-13C3; D-α-Tocopherol-13C3)

Cat. No.: HY-N0683S1

α-Vitamin E-13C3 ((+)-α-Tocopherol-13C3) is the 13C-labeled α-Vitamin E. α-Vitamin E ((+)-α-Tocopherol), a naturally occurring vitamin E form, is a potent antioxidant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-Vitamin E-13C6

((+)-α-Tocopherol-13C6; D-α-Tocopherol-13C6)

Cat. No.: HY-N0683S

α-Vitamin E-13C6 ((+)-α-Tocopherol-13C6) is the 13C-labeled α-Vitamin E. α-Vitamin E ((+)-α-Tocopherol), a naturally occurring vitamin E form, is a potent antioxidant.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Cyclodextrin

Cat. No.: HY-107201

β-Cyclodextrin is a cyclic polysaccharide composed of seven units of glucose (α-D-glucopyranose) linked by α-(1,4) type bonds. β-Cyclodextrin has often been used to enhance the solubility of drugs. β-Cyclodextrin has anti-influenza virus **H1N1** activities.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 500 mg, 1 g